1. Efalizumab.
- Subjects
T cells ,LYMPHOMAS ,EFALIZUMAB ,PSORIASIS ,ANTINEOPLASTIC agents - Abstract
The article presents a case study of a 32-year-old man whose undiagnosed cutaneous T-cell lymphoma progressed whilst receiving efalizumab for psoriasis. It outlines some of the symptoms experienced by the patient after efalizumab discontinuation. The patient's tumours persisted and progressed to involve his chest and back after receiving various antineoplastic regimens.
- Published
- 2009